Cytokine Signalling Forum

Publications





August 18

Arrêt du Tocilizumab après Rémission chez des Patients Atteints de Polyarthrite Rhumatoïde Traités avec du Tocilizumab Seul ou en Association Avec du Méthotrexate: Résultats d'une Étude Prospective Randomisée Contrôlée (deuxième année de l'étude SURPRISE)

Kaneko Y, Kato M, Tanaka Y, Inoo M, Kobayashi-Haraoka H, Amano K, Miyata M, Murakawa Y, Yasuoka H, Hirata S, Tanaka E, Miyasaka N, Yamanaka H, Yamamoto K, Takeuchi T, the SURPRISE study group.
Ann Rheum Dis 2018; 77:1268–1275 DOI: 10.1093/rheumatology/key121

The second-year results from the SURPRISE study show that low disease activity (LDA) can be maintained after discontinuation of tocilizumab with continued methotrexate after remission is achieved. Discontinuation of biologic agents in patients who have achieved remission or low disease activity (LDA) is desirable from a risk–benefit point of view. Compared with TNF inhibitors, little is known regarding TCZ-free remission or LDA, but studies indicate that only a small proportion of patien...

Mots clefs: IL-6, Tocilizumab, Clinical, Efficacy

Traduit par: Noack